


### *Amendments to the Claims*

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (canceled)

2. (previously presented) A process for extracting a natural compound having antidiabetic effect extracted from *Taxus spp*, said process comprising: extracting *Taxus spp* with an organic solvent to obtain an extractum, subjecting the extractum to a diphasic extraction and a chromatography using a macroporous resin column, collecting fractions containing 5-O-methyl-myo-inositol, then concentrating, crystallizing, and filtrating to obtain a powder, recrystallizing the powder to obtain a natural compound of 5-O-methyl-myo-inositol having the formula I:



wherein the organic solvent used for extraction is selected from ethanol, methanol, acetone, and aqueous mixtures thereof, and the solvent used for diphasic extraction is a water insoluble organic solvent.

3. (previously presented) The method according to claim 2, characterized in that said *Taxus spp* is *Taxus yunnanensis* Cheng et L. K. Fu, or *Taxus chinensis* var. *mairei* (Lemee et Levl) Cheng et L. K. Fu.

4. - 5. (canceled)


6. (previously presented) The method according to claim 2, characterized in that the solvent used for diphasic extraction is selected from ethyl acetate, chloroform, dichloromethane and ethyl ether.

7. (canceled)

8. (previously presented) The method according to claim 2, characterized in that the solvent system used for recrystallation is a solvent system selected from ethanol, methanol, acetone, methylethylketone and a mixture thereof.

9. - 10. (canceled)

11. (currently amended) A method for treatment and prevention of a disease related to diabetes comprising administering to a patient in need thereof a medicament that contains extracted natural compound 5-O-methyl-*myo*-inositol having the formula I:



wherein said disease related to diabetes is selected from the group consisting of diabetic cardiovascular, cerebrovessel and glycometabolic disorder-associated diseases.

12. (previously presented) The method according to claim 11, characterized in that said medicament is able to significantly alleviate hyperglycemia of diabetes, inhibit the decomposition of hepatic glycogen and the absorption of glucose, reduce blood fat level, improve the metabolism of free radicals, and protect  $\beta$  cells of the pancreatic island.

13. (previously presented) The method according to claim 11, wherein said method prevents and treats complications from diabetic cardioangiopathy and other glycometabolic disorder-associated diseases in said patient.

14. (previously presented) The method according to claim 11, wherein said method prevents and treats type-II diabetes and complications in terms of diabetic cardioangiopathy in said patient.

15. (previously presented) The method according to claim 11, wherein said treatment and prevention improves the metabolism of free radicals in said patient.